SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
kingkingwang2013
Lv2
2
150 积分
2022-06-13 加入
最近求助
最近应助
互助留言
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
11小时前
待确认
Navigating resistance to ALK inhibitors in the Lorlatinib Era: a comprehensive perspective on NSCLC
4个月前
已完结
An integrated approach to cardioprotection in lymphomas
6个月前
已完结
Selected pharmacologic characteristics of idarubicin and idarubicinol
7个月前
已关闭
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
8个月前
已完结
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
8个月前
已完结
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial
8个月前
已完结
Rates of Ocular Adverse Events Following Intravitreal Faricimab Injections
8个月前
已关闭
Real-World Outcomes of Faricimab in Patients with Previously Treated Neovascular Age-Related Macular Degeneration
8个月前
已完结
Short-Term Outcomes of Faricimab in Patients with Neovascular Age-Related Macular Degeneration on Prior Anti-VEGF Therapy
8个月前
已完结
没有进行任何应助
重复求助了【积分已退回】
8个月前
已找到【积分已退回】
1年前
文章不对
2年前
文章错误【积分已退回】
2年前
已找到【积分已退回】
2年前
时间长没人应答【积分已退回】
2年前
点赞
2年前
点赞
2年前
太感谢了!
2年前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论